Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Women's health (London, England) - 1 Jan 2014

Black Jonathan D, English Diana P, Roque Dana M, Santin Alessandro D

Abstract excerpt

Uterine serous carcinoma (USC) is a highly aggressive variant of endometrial cancer. Although it only represents less than 10% of all cases, it accounts for a disproportionate number of deaths from endometrial cancer. Comprehensive surgical staging followed by carboplatin and paclitaxel chemotherapy represents the mainstay of USC therapy. Vaginal cuff brachytherapy is also of potential benefit in USC. Recent...

Topics

Join the communities discussing this publication.

Class I Phosphatidylinositol 3-Kinases
Cyclin E
Cystadenocarcinoma, Serous
Genes, erbB-2
Neoplasm Recurrence, Local

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Phosphatidylinositol 3-Kinases

Randomized Controlled Trials as Topic

Uterine Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 24328598
DOI: 10.2217/whe.13.72
PMCID: PMC3984476

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.PMID 24328598Read ↗

Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.Semantic proximity Read ↗

Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.Semantic proximity Read ↗

Updates in therapy for uterine serous carcinomaSemantic proximity Read ↗

Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.Semantic proximity Read ↗

Integrated mutational landscape analysis of endometrial stromal sarcoma.Semantic proximity Read ↗

Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma.Semantic proximity Read ↗

Comprehensive Review of Endometrial Cancer: New Molecular and FIGO Classification and Recent Treatment ChangesSemantic proximity Read ↗

Endometrial cancer.Semantic proximity Read ↗

Genomic and Transcriptomic Characterization Revealed the High Sensitivity of Targeted Therapy and Immunotherapy in a Subset of Endometrial Stromal SarcomaSemantic proximity Read ↗

Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.Semantic proximity Read ↗

The brave new world of endometrial cancer : Future implications for adjuvant treatment decisions.Semantic proximity Read ↗

Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.